Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 12, 2013 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Host Analyst Event in New York City

CARMIEL, Israel, June 12, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), will be hosting an analyst event on Thursday, June 20, 2013 at 8:00 AM EDT in New York...
May 29, 2013 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences

CARMIEL, Israel, May 29, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), today announced that senior management will present at three upcoming healthcare...
May 08, 2013 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Present at the Oppenheimer 14th Annual Israeli Conference

CARMIEL, Israel, May 8, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today announced that Dr. David Aviezer, the Company's President and Chief Executive Officer,...
April 29, 2013 07:30 ET | Source: Protalix BioTherapeutics, Inc.

UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease

CARMIEL, Israel, April 29, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that the Mexican Federal Commission for the Protection against Sanitary...
April 02, 2013 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Treats First Gaucher Patient in Phase I Study With PRX-112, an Orally-Administered Enzyme Treatment of Gaucher Disease

CARMIEL, Israel, April 2, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the first patient has been treated in the Company's phase I clinical...
March 18, 2013 14:15 ET | Source: Protalix BioTherapeutics, Inc.

UPLYSO(TM) (alfataliglicerase) Approved in Brazil by ANVISA for the Treatment of Gaucher Disease

NEW YORK and CARMIEL, Israel, March 18, 2013 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) announced today that the Brazilian National Health...
March 07, 2013 08:45 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Receives Approval to Initiate Phase I Study in Gaucher Patients With PRX-112, an Orally-Administered Candidate for the Treatment of Gaucher Disease

CARMIEL, Israel, March 7, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that it has received approval from the Israeli Ministry of Health to...
February 13, 2013 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix Announces New Clinical Data on ELELYSO(TM) to be Presented at the WORLD Symposium 2013

CARMIEL, Israel, Feb. 13, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that new clinical data on ELELYSO™ (taliglucerase alfa) will be...
February 05, 2013 11:43 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Reviewing Partnering and Other Alternatives

CARMIEL, Israel, Feb. 5, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX) (TASE:PLX), confirms, in response to inquiries received this morning and a report appearing in the...
February 05, 2013 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Present at the 15th Annual BIO CEO & Investor Conference

CARMIEL, Israel, Feb. 5, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) today announced that Dr. David Aviezer, the Company's President and Chief Executive Officer,...